close

Agreements

1 206 207 208 209 210 221
Number of results: 4419

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2011-09-29 Almirall (Spain) Nycomed (Switzerland) ebastine (Kestine®) allergic rhinitis, chronic idiopathic urticaria

licensing
supply

Allergic diseases - Dermatological diseases - Immunological diseases Licensing agreement
2011-09-29 Lundbeck (Denmark) Proximagen (UK) novel innovative therapies for serious diseases such as epilepsy, pain and inflammatory disorders serious diseases such as epilepsy, pain and inflammatory disorders

R&D

CNS diseases - Inflammatory diseases - Neurological diseases R&D agreement
2011-09-27 Hypha Discovery (UK) Ferrer Grupo (Spain) low molecular weight natural products to treat microbial infections microbial infections

R&D

Infectious diseases R&D agreement
2011-09-27 Lonza (Switzerland) Mesoblast (Australia) adult stem cell products

manufacturing
production

Regenerative medicine Production agreement
2011-09-27 Silence Therapeutics (UK) undisclosed top 10 pharma company DACC formulated siRNAs undisclosed

R&D

R&D agreement
2011-09-25 Biotec Pharmacon (Norway) Affymetrix (USA) shrimp alkaline phosphatase

Supply

Services contract
2011-09-22 Almirall (Spain) Proteros biostructures (Germany) small molecule inhibitors against a target selected by Almirall in the field of inflammatory diseases inflammatory diseases

R&D

Inflammatory diseases R&D agreement
2011-09-21 CMC Biologics (Denmark-USA) Inspiration Biopharmaceuticals (USA) IB1001 (intravenous recombinant factor IX (rFIX) product) treatment and prevention of bleeding in individuals with hemophilia B

manufacturing
production

Hematological diseases - Genetic diseases - Rare diseases Production agreement
2011-09-21 Sanofi Pasteur (France) University of California, San Diego (USA) acne vaccine and treatment Acne vulgaris

R&D

Dermatological diseases - Infectious diseases R&D agreement
2011-09-19 Merck KGaA, Merck Serono (Germany) Peptimmune (USA) PI-2301 mutliple sclerosis

licensing
development
commercialisation

Neurodegenerative diseases - Autoimmune diseases Licensing agreement
2011-09-19 NeuroVive Pharmaceutical (Sweden) Selvia (UK) new medicines and drug compounds targeting mitochondrial physiology and pathophysiology R&D
2011-09-16 Scil Proteins (Germany) Martin Luther University Halle-Wittenberg (Germany) gastrointestinal tumors.

R&D

Cancer - Oncology R&D agreement
2011-09-15 Teva Pharmaceutical (Israel) Cocrystal Discovery (USA) antiviral therapeutics serious and chronic viral diseases

development
licensing
share purchase

Infectious diseases Development agreement
2011-09-15 Arsanis (USA - MA)

nomination

Infectious diseases Nomination
2011-09-13 Novalix (France) Fondation Jerome Lejeune (France)

R&D

Genetic diseases R&D agreement
2011-09-13 Zobio (The Netherlands) Abbott (USA) biophysics research services in the area of hit matter discovery and characterization undisclosed

R&D
services

R&D agreement
2011-09-13 Oxford BioTherapeutics (UK) Seattle Genetics (USA - WA) antibody-drug conjugates (ADC) for cancer cancer

R&D
development
commercialisation

Cancer - Oncology R&D agreement
2011-09-12 Ark Therapeutics Group (UK) PsiOxus Therapeutics (UK) ColoAd1 programme colorectal cancer Manufacturing
Production
Cancer Oncology
2011-09-12 Silence Therapeutics (UK) InteRNA Technologies (The Netherlands) novel microRNA therapeutics cancer

development

Cancer - Oncology Development agreement
2011-09-08 Sucampo Pharmaceuticals (USA) Numab AG (Switzerland) antibody technology

R&D

R&D agreement